Briefing Summary: US FDA Posts Advisory Committee Materials for Celltrion’s Proposed Biosimilar to Remicade– FEB 9, 2016 (AAC)
The US FDA has posted details, including company and FDA Briefing Materials, for the Tuesday, February 9, 2016 Arthritis Advisory Committee (AAC) meeting. The Committee will discuss a biologics license application (BLA) for Celltrion Inc.’s Remsima (CT- P13), a proposed biosimilar to Janssen Biotech Inc.'s Remicade (infliximab).
See the SAC Tracker report